Rare Disease

Latest News

Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment
Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment

August 6th 2024

A new method using 2 single-guide RNA/Cas9 tools to target 3 specific COL7A1 gene segments with harmful mutations successfully removed up to 95% of those segments.

Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%
Pediatric Emergency Department Visits with Dystrophic Epidermolysis Bullosa More Frequent in Summer; Hospitalization Rates Exceed 50%

July 29th 2024

Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita
Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita

July 25th 2024

Oleogel-S10 Proves Effective in Decreasing Dressing Change Frequency and Costs for Epidermolysis Bullosa Patients
Oleogel-S10 Proves Effective in Decreasing Dressing Change Frequency and Costs for Epidermolysis Bullosa Patients

July 15th 2024

Study Finds Novel Pathogenic Variants, Inflammatory Cytokines, and Activated JAK-STAT Signaling in Patients With Congenital Ichthyosis
Study Finds Novel Pathogenic Variants, Inflammatory Cytokines, and Activated JAK-STAT Signaling in Patients With Congenital Ichthyosis

July 10th 2024

Video Interviews
Latest CME Events & Activities

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

October 16, 2024

Register Now!

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis

November 21, 2024 - December 5, 2024

View More

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

More News

© 2024 MJH Life Sciences

All rights reserved.